Information since 9 Mar 2026, 11:12 a.m.
| Non-Departmental Publications - News and Communications |
|---|
|
Jun. 24 2026
Competition and Markets Authority Source Page: Hydrocortisone tablets: alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct (50277) Document: Annexes (PDF) News and Communications Found: consistent with its views on off-label use of drugs expressed to Cinven in November 2014: ‘The off-patent drugs bill |